Crism Therapeutics (LSE:CRTX) EPS (Basic): £-0.05 (TTM As of Jun. 2025)


LSE:CRTX Crism Therapeutics Corp LSE:CRTX
37 GF Score
Price £0.10
! 3 Warning Signs
View Full Analysis

What is Crism Therapeutics EPS (Basic)?

Crism Therapeutics LSE:CRTX -2.44% 37 EPS (Basic) is £-0.05 as of Jun. 2025. GuruFocus rates LSE:CRTX with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

Crism Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Jun. 2025 was £-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2025 was £-0.05.

Crism Therapeutics's EPS (Diluted) for the six months ended in Jun. 2025 was £-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was £-0.05.

Crism Therapeutics's EPS without NRI for the six months ended in Jun. 2025 was £-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2025 was -0.05.

During the past 3 years, the average EPS without NRI Growth Rate was 44.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 40.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 23.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Crism Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 44.00% per year. The lowest was -8.80% per year. And the median was 18.30% per year.

Crism Therapeutics  (LSE:CRTX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Crism Therapeutics EPS (Basic) Related Terms

Crism Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Crism Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crism Therapeutics EPS (Basic) Chart

Crism Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.29 -0.11 -0.29 0.08 -0.02

Crism Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.44 -0.01 -0.00 -0.02 -0.03
LSE:CRTX
37GF Score
Crism Therapeutics Corp LSE:CRTX
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crism Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Crism Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.607-0)/32.181
=-0.02

Crism Therapeutics's Basic EPS for the quarter that ended in Jun. 2025 is calculated as

Basic EPS (Q: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.93-0)/32.678
=-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of £-0.05 mean?
Crism Therapeutics (LSE:CRTX) has a EPS (Basic) of £-0.05 as of Jun. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Crism Therapeutics and its competitors.
Is Crism Therapeutics' EPS (Basic) too high?
Crism Therapeutics' current EPS (Basic) is £-0.05. Overall, Crism Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' EPS (Basic) compare to VRTX and REGN?
Crism Therapeutics' EPS (Basic) of £-0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Crism Therapeutics and its competitors. Crism Therapeutics's current EPS (Basic) is £-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (LSE:CRTX) has a current EPS (Basic) of £-0.05. The current EPS (Basic) is £-0.05. Crism Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Crism Therapeutics (LSE:CRTX), the current EPS (Basic) is £-0.05 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crism Therapeutics Business Description

Address Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
37GF Score

Get the complete analysis for LSE:CRTX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.10
Price